Neos Therapeutics (NEOS) Reports Q2 Loss of $1.65/Share
- Stocks face worst month since September, yen swings after BoJ
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil prices on track to snap two-week losing streak
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Neos Therapeutics Announces Second Quarter 2016 Financial Results
August 11, 2016 7:01 AM EDTDALLAS/FORT WORTH, Texas, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced financial results for the second quarter ended June 30, 2016 and provided a business update.
We are pleased with the steady increase in demand for Adzenys XR-ODT since the launch on May 16, 2016. We are receiving positive feedback from both physicians and patients, and adoption across multiple age groups has been encouraging. We anticipate... More